Filana Therapeutics, Inc.
FLNANASDAQHealthcareBiotechnology
Previous close
$0.961
+$0.0185 · +1.96%
Aug 21, 4:00 PM ET
Pre-market
$0.94
−$0.021 · -2.19%
Aug 24, 7:00 AM ET
FLNA company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteFilana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Richard Jon Barry
- Listed since
- Jul 14, 2000
- Employees
- 19
Market position
Day range
Current $0.961
$0.9426$0.961
52-week range
Current $0.961
$0.85$4.98
- Open
- $0.947
- Previous close
- $0.9425
- Volume
- 107.57K
- 0.29× average
- Average volume
- 372.86K
- Average daily volume
- Market cap
- 46.42M USD
- Beta
- -0.69
- Market reference 1
- 50-day average
- $1.0728
- -10.42% below average
- 200-day average
- $1.826
- -47.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.51M USD
- P/E (TTM)
- -1.1×
- P/B (TTM)
- 0.73×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.04×
- Earnings yield
- -91.88%
- Free cash flow yield
- -33.16%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -122.27%
- Return on assets
- -76.86%
- Return on invested capital
- -128.00%
Financial health
- Debt / equity
- 0×
- Current ratio
- 2.23×
Financial statements
Income trends
Operating income
−95.39M USD+32.56%
Net income
−90.97M USD-273.73%
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 936K USD | — | — | — | — |
| Gross profit | −936K USD | — | — | — | — |
| Research and development | 26.59M USD | 69.64M USD | 89.42M USD | 68.03M USD | 24.81M USD |
| Selling, general, and administrative | 67.86M USD | 71.81M USD | 16.53M USD | 11.99M USD | 8.06M USD |
| Operating expenses | 94.45M USD | 141.45M USD | 105.96M USD | 80.02M USD | 32.87M USD |
| Interest income | 4.62M USD | 8.51M USD | 7.83M USD | 2.78M USD | 49K USD |
| Depreciation and amortization | 936K USD | 1.13M USD | 1.53M USD | 1.3M USD | 534K USD |
| Operating income | −95.39M USD | −141.45M USD | −105.96M USD | −80.02M USD | −32.87M USD |
| Net income | −90.97M USD | −24.34M USD | −97.22M USD | −76.25M USD | −32.39M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 100%
- 8 beats, 0 misses, 0 met estimates
- Average EPS surprise
- +27.73%
- 8 comparable reports
- Latest EPS result
- -0.18
- Estimate -0.23 · Beat by 20.00%
EPS: actual versus estimate
Recent quarterly results
ActualEstimate
FLNA news
FLNA peers
ETFs holding FLNA
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.38M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 569.52K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Vanguard Health Care ETFVHT- Market value
- 134.94K
- Weight
- 0.00%
- AUM
- 20.9B USD
- Expense ratio
- 0.09%
- Price / 1D
- $327.7+1.24%
Continue in GoAI
Research FLNAresearch.disclaimer